Takeda Pharmaceutical's Cash from Financing Activities rose 7102.32% to -$1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.8 billion, marking a year-over-year decrease of 4048.83%. This contributed to the annual value of -$4.9 billion for FY2025, which is 10072.69% down from last year.
Per Takeda Pharmaceutical's latest filing, its Cash from Financing Activities stood at -$1.3 billion for Q4 2025, which was up 7102.32% from -$81.3 million recorded in Q3 2025.
Takeda Pharmaceutical's Cash from Financing Activities' 5-year high stood at $2.0 billion during Q2 2024, with a 5-year trough of -$4.3 billion in Q4 2024.
For the 5-year period, Takeda Pharmaceutical's Cash from Financing Activities averaged around -$1.4 billion, with its median value being -$1.4 billion (2021).
Examining YoY changes over the last 5 years, Takeda Pharmaceutical's Cash from Financing Activities showed a top increase of 58206.65% in 2024 and a maximum decrease of 68739.72% in 2024.
Quarter analysis of 5 years shows Takeda Pharmaceutical's Cash from Financing Activities stood at -$1.5 billion in 2021, then plummeted by 108.24% to -$3.1 billion in 2022, then surged by 78.52% to -$661.4 million in 2023, then plummeted by 552.41% to -$4.3 billion in 2024, then surged by 71.02% to -$1.3 billion in 2025.
Its Cash from Financing Activities was -$1.3 billion in Q4 2025, compared to -$81.3 million in Q3 2025 and -$1.5 billion in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value